Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2Sarcoma 2Genitourinary 2Other solid neoplasm 1Gastrointestinal 1CNS 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Magnetic Resonance Spectroscopy 15Surgical Procedures, Operative 14Radiotherapy 13Blood Specimen Collection 13Biopsy 13atezolizumab 12Gemcitabine 12fludarabine 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 7liposomal doxorubicin 5abemaciclib 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × peposertib × Sarcoma × Clear all
NCT04555577 2026-05-20

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

M.D. Anderson Cancer Center

Phase 1 Recruiting
29 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡